PT  - JOURNAL ARTICLE
AU  - Kozanli, Eva
AU  - Winkel, Angelique M.A.M.
AU  - Han, Alvin X.
AU  - van den Brink, Sharon
AU  - van den Brandt, Annemarie
AU  - Haverkort, Milly E.
AU  - Euser, Sjoerd
AU  - Russell, Colin A.
AU  - de Jong, Menno D.
AU  - van Houten, Marlies A.
AU  - van Lelyveld, Steven F.L.
AU  - Eggink, Dirk
TI  - Shortened SARS-CoV-2 shedding in saliva during early Omicron compared to wild-type pandemic phase
AID  - 10.1101/2024.09.11.24313457
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.11.24313457
4099  - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313457.short
4100  - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313457.full
AB  - This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus-infected and Omicron-infected household cohorts. Pre-existing immunity in participants likely shortens duration of viral shedding and lowers viral load peaks. Dense saliva sampling can be a convenient tool to study viral load dynamics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe SARSLIVA 1 study was supported by internal funds from the National Institute for Public Health and the Environment (RIVM), and by The Netherlands Organization for Health Research and Development (ZonMw), grant number 10430012010017, financed in part by The Netherlands Ministry of Health, Welfare and Sport. E. A. M. S. reports employment with RIVM, who supported the research for this work. Moreover, both SARSLIVA studies were supported by internal funds from Spaarne Gasthuis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants. This study was reviewed and approved by the Medical Ethical Committee of the Amsterdam University Medical Centre, The Netherlands (reference number 2020.436 (SARSLIVA 1) and 2022.0073 (SARSLIVA 2.0)).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDe-identified data collected for the study, including individual participant data collected during the study and a data dictionary, will be shared upon reasonable request. These requests will be discussed with all project partners (Spaarne Gasthuis, Public Health Service Kennemerland and RIVM). Requests should be directed to s.van.lelyveld{at}spaarnegasthuis.nl or dirk.eggink{at}rivm.nl. These requests will be reviewed and approved by the investigator and project partners based on scientific merit. To gain access, data requesters will need to sign a data access agreement. Privacy-sensitive data, which is traceable to the participant, will not be shared.